There was a strong link between restless legs syndrome and insomnia that was not previously known or expected. This relationship, whether causal or not, could have a role in future treatment options. This is a very challenging disorder that [needs to be studied deeper to determine potential treatments (http://www.sciencedaily.com/releases/2018/01/180028160856.htm) and/or treatments (http://www.sciencedaily.com/releases/2018/01/180028082616.htm)] which should be made available to you. When one is looking to join a Restless legs clinical trial, [Power](http://www.withpower.
Given the limited evidence, common therapies for restless legs syndrome include sleep aids, nonbenzodiazepines, stimulants, and antipsychotic agents. No therapies are supported by strong evidence, with many needing further investigation. The most effective strategy for relieving symptoms at least temporarily may be the reduction of sleep fragmentation.
There currently is no cure for RLS, but many treatments have proven useful, for example, in alleviating the subjective symptoms and improving the quality of life, and many medications have been effective in the last 15 years. The disease, however, has a high remission rate and, for many patients, a good quality of life with excellent symptom control, and no significant long-term adverse effects of medication. The aim of this paper is to give an overview of the treatment options for RLS, to compare them and provide the evidence to support treatment decisions.
About 3 million Americans currently have this syndrome according to the data compiled by the RLS Foundation. This results in considerable distress to the affected person and significant economic and social costs.
Signs and symptoms of RLS are typically intermittent, with symptoms not being noticed outside of the patient's normal waking hours. Patients tend to avoid activity and rest until they recognize their symptoms. The main symptom is a strong urge to move the legs. Some patients with RLS experience muscle cramping, numbness, and even itching, particularly with activity or exertion. The risk of developing RLS increases in people who are older, have insomnia, and have other health problems such as Parkinson's disease or a neurological disorder. RLS most commonly affects women in their 40s and 60s. Approximately 50% of affected patients initially present with an identifiable primary cause for symptoms.
In many cases, RLS cannot be completely explained by medical, behavioral, and psychological factors alone. These data indicate that the genetic predisposition, metabolic abnormalities, and environmental toxins may operate in combination to produce RLS.
Many subjects prescribed medications in conjunction with other treatments reported good or excellent improvements in sleepiness symptoms. Results from a recent clinical trial could affect the choice of appropriate treatments for RLS.
Results from a recent clinical trial suggest that the efficacy of CBT in patients with RLS is not limited to a single type of treatment method(s) but may actually be correlated to the patient's current level of pain and the degree of interference with everyday activities. Results from a recent clinical trial are of importance to inform those with RLS in managing their disease and in designing new therapeutic strategies that may help to preserve quality of life.
Recent findings of the present study indicate that there are no significant differences in improvement between the placebo and drug groups. However, if the drug is used, the therapeutic effect is significantly more effective than a placebo, and treatment of RLS patients with amitriptyline can be recommended.
Many of these patients should consider clinical trials for RLS because a cure has not been found. The lack of effective treatments for chronic RLS is a public health concern. These patients are at high risk to develop other co-morbid conditions. The health impact of RLS should continue to be a prominent component of the focus of RLS clinical trials and their design and analysis should continue to be refined.
Treating restless legs syndrome with iron supplements in addition to levodopa did not relieve the underlying problem nor reduce the frequency of restless legs. There was significant iron deficiency among the restless legs group.
Recent findings show that these patients with RLS find improvement in HRQOL after treatment with pramipexole, a drug currently available under the brand name Extension. This improvement is similar to the improvement that patients with RLS can expect in clinical trials of other treatments for RLS, confirming that patients in clinical trials and those receiving the treatment do expect improvements in HRQOL. Despite these improvements in HRQOL, the level of patient satisfaction with treatment was low. In addition, improvement in HRQOL may require a longer time course of treatment than previously thought.